

# **L** Core Project R03OD030604

## O Details

| Projects        | Name   | Award        | Publications   | Repositories   | Analytics    |
|-----------------|--|--------------|----------------|----------------|--------------|
| 1R03OD030604-01 | Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing | \$297,000.00 | 9 publications | 0 repositories | 0 properties |

## Publications

Published works associated with this project.

| ID         | Title  | Authors               | RC<br>R   | SJ<br>R | Cita<br>tion<br>s | Cit./<br>yea<br>r | Journal            | Publ<br>ishe<br>d | Upda<br>ted |
|------------|--|-----------------------|-----------|---------|-------------------|-------------------|--------------------|-------------------|-------------|
| 35337371 🗹 | Considerations and challenges for sexaware drug repurposing. | Fisher,<br>Jennifer L | 1.3<br>58 | 0       | 14                | 4.66<br>7         | Biol Sex<br>Differ | 2022              | Sep<br>17,  |

|                                   |  | 4<br>more<br>Lasseigne<br>, Brittany<br>N                         |           |   |   |     |                            |      | 2025<br>(just<br>now)               |
|-----------------------------------|--|---|-----------|---|---|-----|----------------------------|------|-------------------------------------|
| 37217845 🗹<br>DOI 🗹               | Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and        | Wilk, Elizabeth J9 more Lasseigne , Brittany N                    | 0.5<br>51 | 0 | 4 | 2   | Mol Med                    | 2023 | Sep<br>17,<br>2025<br>(just<br>now) |
| 37533331 🖸                        | Evaluating cancer cell line and patient-<br>derived xenograft recapitulation of tumor<br>and non-disease | Williams,<br>Avery S<br>2<br>more<br>Lasseigne<br>, Brittany<br>N | 0.5<br>02 | 0 | 4 | 2   | Cancer<br>Rep<br>(Hoboken) | 2023 | Sep<br>17,<br>2025<br>(just<br>now) |
| 36602970 <b>♂</b><br>DOI <b>♂</b> | Ten simple rules for using public biological data for your research.                                     | Oza,<br>Vishal H<br>9<br>more<br>Lasseigne<br>, Brittany<br>N     | 0.4<br>34 | 0 | 3 | 1.5 | PLoS<br>Comput<br>Biol     | 2023 | Sep<br>17,<br>2025<br>(just<br>now) |

| 37362157 <b>2</b>                 | Sex-biased gene expression and gene-<br>regulatory networks of sex-biased adverse<br>event drug targets  | Fisher, Jennifer L2 more Lasseigne , Brittany                       | 0.2       | 0 | 1 | 0.5 | bioRxiv                     | 2023 | Sep<br>17,<br>2025<br>(just<br>now) |
|-----------------------------------|--|---|-----------|---|---|-----|-----------------------------|------|-------------------------------------|
| 37824797 ♂<br>DOI ♂               | Computational Advancements in Cancer<br>Combination Therapy Prediction.                                  | Flanary,<br>Victoria L<br>3<br>more<br>Lasseigne<br>, Brittany<br>N | 0.2<br>11 | 0 | 2 | 1   | JCO Precis<br>Oncol         | 2023 | Sep<br>17,<br>2025<br>(just<br>now) |
| 37090499 ♂<br>DOI ♂               | Evaluating cancer cell line and patient-<br>derived xenograft recapitulation of tumor<br>and non-disease | Williams,<br>Avery S<br>2<br>more<br>Lasseigne<br>, Brittany<br>N   | 0         | 0 | 0 | 0   | bioRxiv                     | 2023 | Sep<br>17,<br>2025<br>(just<br>now) |
| 38167211 <b>2</b><br>DOI <b>2</b> | Sex-biased gene expression and gene-<br>regulatory networks of sex-biased adverse<br>event drug targets  | Fisher,<br>Jennifer L<br>2<br>more<br>Lasseigne                     | 0         | 0 | 4 | 4   | BMC<br>Pharmacol<br>Toxicol | 2024 | Sep<br>17,<br>2025<br>(just<br>now) |

|   |  | , Brittany<br>N  |   |   |   |   |                  |      |                                     |
|---|--|--|---|---|---|---|------------------|------|-------------------------------------|
| <u>38531616</u> <b>♂</b><br><u>DOI</u> <b>♂</b> | Signature reversion of three disease-<br>associated gene signatures prioritizes<br>cancer drug repurposi | Fisher,<br>Jennifer L<br>7<br>more<br>Lasseigne<br>, Brittany<br>N | 0 | 0 | 1 | 1 | FEBS Open<br>Bio | 2024 | Sep<br>17,<br>2025<br>(just<br>now) |

## Notes

RCR Relative Citation Ratio

SJR Scimago Journal Rank

### Publications (cumulative)





| Name | Tags | Last Commit | Avg Issue | Avg PR | Languages | License | Readme | Contributing | Dependencies |
|------|------|-------------|-----------|--------|-----------|---------|--------|--------------|--------------|
|      |      |             |           |        | No data   |         |        |              |              |

#### Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Avg Issue/PR Average time issues/pull requests stay open for before being closed.

Only the main /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

## Analytics

Traffic metrics of websites associated with this project.

### Notes

Active Users <u>Distinct users who visited the website</u> **.** 

New Users <u>Users who visited the website for the first time</u> **.** 

Engaged Sessions <u>Visits that had significant interaction</u> **?**.

"Top" metrics are measured by number of engaged sessions.

Built on Sep 17, 2025

Developed with support from NIH Award U54 OD036472